{
  "resultsSection": {
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "title": "Absolute Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)",
          "description": "FEV1 measures how much air a person can exhale during the first second of a forced breath.\n\nAdjusted means are reported.",
          "paramType": "MEAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Milliliters (mL)",
          "groups": [
            {
              "id": "OG000",
              "title": "Placebo",
              "description": "Participants received subcutaneous..."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "120"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Class Title",
              "categories": [
                {
                  "title": "Category Title",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "12",
                      "spread": "2",
                      "lowerLimit": "8",
                      "upperLimit": "16",
                      "comment": "Not applicable"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26",
          "description": "ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) in accordance with the revised response criteria for malignant lymphoma (Cheson 2007)...",
          "populationDescription": "ITT population included all participants who were randomized.",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Week 26",
          "groups": [
            {
              "id": "OG001",
              "title": "Rituximab-EU",
              "description": "Participants received Rituximab-EU intravenous (IV) infusion at a dose of 375 milligrams per meter square (mg/m\\^2) on Day 1, 8, 15, and 22. The maximum dose that could be infused in 1 day was 1125 mg."
            },
            {
              "id": "OG002",
              "title": "PF-05280586",
              "description": "Participants received PF-05280586 IV infusion at a dose of 375 mg/m\\^2 on Day 1, 8, 15, and 22. The maximum dose that could be infused in 1 day was 1125 mg."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG001",
                  "value": "198"
                },
                {
                  "groupId": "OG002",
                  "value": "196"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Class Title 0G001 and 0G002",
              "categories": [
                {
                  "title": "Category Title 0G001 and 0G002",
                  "measurements": [
                    {
                      "groupId": "OG001",
                      "value": "70.7",
                      "spread": "4",
                      "lowerLimit": "63.8",
                      "upperLimit": "76.9",
                      "comment": "Comment 0G001"
                    },
                    {
                      "groupId": "OG002",
                      "value": "75.5",
                      "spread": "6",
                      "lowerLimit": "68.9",
                      "upperLimit": "81.4",
                      "comment": "Comment 0G002"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    }
  }
}